文献速递MDS 与骨髓增殖性肿瘤白血病

非朗格汉斯细胞组织细胞增生症成人患者中髓系肿瘤高发

High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis.
PubMed 文献 · Blood · 2017-07-05

在189例Erdheim-Chester病(ECD)及混合性组织细胞增生症(MH)多机构队列中,10.1%(19/189)患者合并髓系肿瘤,最常见为骨髓增殖性肿瘤、骨髓增生异常综合征或MDS/MPN重叠综合征。分子分析常检出髓系肿瘤驱动突变与组织细胞增生症特征突变共存。合并髓系恶性肿瘤者诊断时年龄更大且更常见MH。

要点

  • ECD/MH成人患者中10.1%(19/189)合并髓系肿瘤。
  • 髓系肿瘤驱动突变(如JAK2V617F、CALR)可与组织细胞增生症突变(如BRAFV600E、MAP2K1)共存。
  • 合并髓系恶性肿瘤者诊断时年龄更大,更常表现为MH。

核心结论

  • ECD和MH成人患者中髓系肿瘤发生频繁,部分病例因组织细胞增生症与髓系肿瘤携带不同激酶突变而对激酶靶向治疗反应不一致且不良。
  • 数据强调对成人组织细胞增生症患者评估合并髓系肿瘤具有临床重要性。

研究设计与样本

  • 多机构队列研究,纳入189例ECD及ECD重叠朗格汉斯细胞组织细胞增生症(混合性组织细胞增生症,MH)患者。

主要发现

  • 10.1%(19/189)的ECD患者合并髓系肿瘤,最常见为骨髓增殖性肿瘤(MPN)、骨髓增生异常综合征(MDS)或混合性MDS/MPN重叠综合征(包括慢性粒单核细胞白血病)。
  • 分子分析常检出髓系肿瘤标志性驱动突变(如JAK2V617F和CALR突变)与组织细胞增生症特征突变(如BRAFV600E和MAP2K1突变)共存。
  • 合并髓系恶性肿瘤的组织细胞增生症患者诊断时年龄显著更大,且更常见表现为MH。
  • 部分病例中,组织细胞增生症与髓系肿瘤存在不同的激酶突变,导致对激酶导向靶向治疗的反应不一致且不良。

临床怎么用

  • 作者认为,这些数据强调了对成人组织细胞增生症患者评估合并髓系肿瘤的临床重要性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis that most commonly affects adults and is driven by a high frequency of mutations in BRAF, MAP2K1, and kinases promoting MAPK signaling. Because of the relative rarity of ECD, key clinical features of the disease may not be well defined. Across a multi-institutional cohort of 189 patients with ECD and ECD overlapping with Langerhans cell histiocytosis (so-called mixed histiocytosis [MH]), we identified an unexpected and heretofore undescribed frequent occurrence of myeloid neoplasms among patients with ECD and MH. Some 10.1% (19/189) of patients with ECD have an overlapping myeloid neoplasm, most commonly occurring as a myeloproliferative neoplasm (MPN), myelodysplastic syndrome (MDS), or mixed MDS/MPN overlap syndrome (including chronic myelomonocytic leukemia). Consistent with this, molecular analysis frequently detected hallmark driver mutations of myeloid neoplasms (such as JAK2V617F and CALR mutations) coexisting with those characteristic of histiocytosis (such as BRAFV600E and MAP2K1 mutations). Histiocytosis patients diagnosed with a concomitant myeloid malignancy were significantly older at diagnosis and more commonly presented with MH than those without a myeloid malignancy. In some cases, the presence of distinct kinase mutations in the histiocytosis and myeloid neoplasm resulted in discordant and adverse responses to kinase-directed targeted therapies. These data highlight the clinical importance of evaluating adults with histiocytosis for a concomitant myeloid neoplasm.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Papo M, Diamond EL, Cohen-Aubart F, et al. High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood. 2017. PMID: 28679734. doi:10.1182/blood-2017-01-761718

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。